A poor-quality generic drug for the treatment of visceral leishmaniasis: a case report and appeal
about
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisMind the gaps--the epidemiology of poor-quality anti-malarials in the malarious world--analysis of the WorldWide Antimalarial Resistance Network database.How far are we from visceral leishmaniasis elimination in Bangladesh? An assessment of epidemiological surveillance data.Emerging and reemerging neglected tropical diseases: a review of key characteristics, risk factors, and the policy and innovation environment.Chemical and bioassay techniques to authenticate quality of the anti-leishmanial drug miltefosineEthical challenges in designing and conducting medicine quality surveys.Validation of ELISA for quantitation of artemisinin-based antimalarial drugs.Assessing the impact of substandard copy medicines in developing countries: the experience with imatinib copies.Pattern recognition techniques applied to the study of leishmanial glyceraldehyde-3-phosphate dehydrogenase inhibition.Evaluating drug resistance in visceral leishmaniasis: the challenges.Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpointIdentification of electronic and structural descriptors of adenosine analogues related to inhibition of leishmanial glyceraldehyde-3-phosphate dehydrogenase.Why miltefosine-a life-saving drug for leishmaniasis-is unavailable to people who need it the most.
P2860
Q28271849-672828B6-C36A-4BD4-B99F-7039FB5F8858Q30486867-337DC37C-AE94-4A66-92DA-0FAE9E37E4F5Q34075053-A385E58A-1258-459B-8C8D-9CCDAAD4FC29Q34297640-0A684721-B81A-4543-858A-D78CF02DE8E4Q35681782-1A6728D9-4197-4F3D-AC13-E1FBD73E5859Q37020706-8AF35998-123A-44A3-9B39-55D5A839E6F8Q37372616-277B9DE3-54F7-4363-8552-6D22ED67851BQ38154622-F3CB2500-7F8B-4B65-A60E-72C1CBCA7303Q38345966-2F99A7F8-F94E-40CC-899A-DAC31167AB47Q39014583-1AF897F3-6CE4-484F-9FE4-3060594AD1FDQ42329781-647CC6F4-7038-447A-B07A-EF7FF009B378Q51030933-FB4A6A02-FC7A-4579-9D54-0C994062A958Q54961274-68B903F8-D5C9-4CC3-9258-5C2962C01AFA
P2860
A poor-quality generic drug for the treatment of visceral leishmaniasis: a case report and appeal
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A poor-quality generic drug fo ...... asis: a case report and appeal
@ast
A poor-quality generic drug fo ...... asis: a case report and appeal
@en
A poor-quality generic drug fo ...... asis: a case report and appeal
@nl
type
label
A poor-quality generic drug fo ...... asis: a case report and appeal
@ast
A poor-quality generic drug fo ...... asis: a case report and appeal
@en
A poor-quality generic drug fo ...... asis: a case report and appeal
@nl
prefLabel
A poor-quality generic drug fo ...... asis: a case report and appeal
@ast
A poor-quality generic drug fo ...... asis: a case report and appeal
@en
A poor-quality generic drug fo ...... asis: a case report and appeal
@nl
P2093
P2860
P3181
P1476
A poor-quality generic drug fo ...... asis: a case report and appeal
@en
P2093
Gerard J Schoone
Jos H Beijnen
Peter J de Vries
Teunis A Eggelte
P2860
P3181
P356
10.1371/JOURNAL.PNTD.0001544
P407
P577
2012-05-29T00:00:00Z